DFV890 for Knee Osteoarthritis

Recruiting in Palo Alto (17 mi)

+24 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Novartis Pharmaceuticals

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called DFV890 to see if it can help people with painful knee osteoarthritis. The study will check if the medication can reduce knee pain and improve how well the knee works. Participants will be monitored for safety and how well they tolerate the medication.

Research Team

Eligibility Criteria

Adults aged 50-80 with knee osteoarthritis, pain in the target knee for most days over the past 3 months, and certain levels of inflammation as shown by blood tests and MRI. They must weigh at least 50 kg with a BMI of 18-35 kg/m2. Excluded are those with other arthritis types, severe malalignment in their knee, certain blood disorders or infections, or using prohibited medications.

Inclusion Criteria

Are you able to undergo an MRI examination with IV contrast (paid for by the study)?

Are you between the ages of 50 and 80?

Do you have mild to moderate knee pain due to osteoarthritis?

See 1 more

Exclusion Criteria

Have you had a partial or total knee replacement?

Have you had any other knee surgery on either knee within the past 6 months?

Treatment Details

Interventions

DFV890 (Other)
Placebo (Other)

Trial OverviewThe trial is testing DFV890's effectiveness compared to a placebo in reducing symptoms of knee osteoarthritis. Participants will be randomly assigned to receive either DFV890 or a placebo without knowing which one they're getting (double-blinded). The study spans up to 21 weeks including screening, treatment, and follow-up periods.

Participant Groups

2Treatment groups

Active Control

Placebo Group

Group I: DFV890Active Control1 Intervention

DFV890

Group II: PlaceboPlacebo Group1 Intervention

Placebo